Middle East and Africa Offsite Sterilisation Service Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Offsite Sterilisation Service Market Overview

The Middle East and Africa offsite sterilisation service market was valued at USD 53.78 million in 2025 and is projected to reach USD 78.25 million by 2033, growing at a CAGR of 4.80% from 2026 to 2033. The market is witnessing steady growth driven by increasing demand for sterile medical devices, expanding healthcare infrastructure, and rising outsourcing of sterilisation processes by healthcare facilities and medical device manufacturers.

The growing focus on infection prevention and control, coupled with stricter regulatory requirements for medical device sterilisation, is encouraging hospitals, pharmaceutical companies, and device manufacturers across the region to utilize specialized offsite sterilisation providers. Ethylene oxide (EtO), gamma irradiation, electron beam (E-beam), and other contract sterilisation services are gaining wider adoption due to their ability to ensure compliance, scalability, and operational efficiency. Additionally, increasing investments in healthcare modernization, growing medical device production, and the expansion of pharmaceutical and biotechnology sectors are supporting the demand for reliable offsite sterilisation services throughout the Middle East and Africa.

Key Market Trends & Insights

• Saudi Arabia dominated the Middle East and Africa offsite sterilisation service market with the largest revenue share of 34.28% in 2025, supported by expanding healthcare infrastructure, increasing medical device consumption, and strong government healthcare investments.
• The Ethylene Oxide Sterilisation segment led the market with a 44.28% share in 2025, driven by its extensive compatibility with heat- and moisture-sensitive medical devices and complex healthcare products.
• United Arab Emirates (UAE) is expected to be the fastest-growing country at a CAGR of 7.4% from 2026 to 2033, fueled by healthcare sector expansion, rising medical device imports, and increasing adoption of outsourced sterilisation services.
• Gamma Sterilisation are the fastest-growing service technology type, projected to register a CAGR of 7.2%, reflecting the surge in demand for high-volume sterilisation of single-use medical products and pharmaceutical packaging
• The Medical Devices segment dominated the product type category with a 39.67% revenue share in 2025, led by rising production and consumption of sterile medical products across hospitals and healthcare facilities.
• Medical Device Sterilisation accounted for 42.54% of the market, preferred by increasing demand for sterile disposable products, diagnostic devices, and implantable medical equipment.
• The Pharmaceutical Sterilisation segment is the fastest-growing application category, with a CAGR of 7.3%, driven by increasing pharmaceutical manufacturing activities and expanding demand for sterile drug products.

Market Size & Forecast

• Global Market Value (2025): USD 53.78 Million
• Expected Market Value (2033): USD 78.25 Million
• Forecast CAGR (2026–2033): 4.80%
• Leading Country in 2025: Saudi Arabia
• Fastest Growing Country: United Arab Emirates

Report Scope and Middle East and Africa Offsite Sterilisation Service Market Segmentation

Middle East and Africa Offsite Sterilisation Service Market Trends

Trend: Increasing Outsourcing of Sterilisation Services by Healthcare and Medical Device Manufacturers

Hospitals, pharmaceutical companies, and medical device manufacturers are increasingly outsourcing sterilisation activities to specialized offsite service providers to improve operational efficiency, ensure regulatory compliance, and reduce capital expenditure associated with in-house sterilisation facilities. The growing complexity of medical devices and rising demand for sterile healthcare products are accelerating the adoption of contract sterilisation services across the region. Additionally, advancements in ethylene oxide (EtO), gamma irradiation, and electron beam technologies are enabling service providers to offer scalable, validated, and cost-effective sterilisation solutions that support evolving healthcare and life sciences requirements. For instance, in March 2024, Sterigenics announced continued investments in global sterilisation capacity and operational enhancements to support growing demand from medical device manufacturers seeking reliable outsourced sterilisation services.

Middle East and Africa Offsite Sterilisation Service Market Dynamics

Key Market Driver: Rising Demand for Sterile Medical Devices and Infection Prevention

The expanding healthcare sector and increasing focus on infection prevention are creating substantial demand for offsite sterilisation services across the Middle East and Africa. Hospitals, medical device manufacturers, and pharmaceutical companies are relying on specialized sterilisation providers to ensure product safety, regulatory compliance, and consistent sterility assurance. Growing surgical procedure volumes, rising healthcare expenditures, and stricter quality standards are further accelerating the adoption of outsourced sterilisation solutions, enabling organizations to reduce operational burdens while maintaining high levels of patient safety and product quality. For instance, in February 2024, Sotera Health Company highlighted increasing demand for contract sterilisation services from healthcare and medical technology customers, driven by expanding global requirements for sterile medical products.

Key Restraint/Challenge: Limited Availability of Advanced Sterilisation Infrastructure

A significant restraint in the Middle East and Africa offsite sterilisation service market is the limited availability of advanced sterilisation infrastructure and specialized service facilities across several countries. Establishing and operating sterilisation centers requires substantial investment in equipment, regulatory approvals, environmental controls, and technical expertise. The high cost of facility development, combined with complex compliance requirements and logistical challenges associated with transporting medical products, can restrict market expansion and reduce service accessibility for healthcare organizations and manufacturers in developing markets.

For instance, in January 2024, industry stakeholders across multiple emerging markets emphasized the need for additional sterilisation capacity and infrastructure investments to address growing healthcare demand and support regional medical device manufacturing activities.

Key Market Opportunity: Expansion of Medical Device Manufacturing and Healthcare Infrastructure

The expansion of medical device manufacturing capabilities and healthcare infrastructure presents a significant opportunity for offsite sterilisation service providers in the Middle East and Africa. Increasing investments in local production, healthcare modernization programs, and pharmaceutical development are creating demand for reliable, compliant sterilisation solutions. The establishment of new healthcare facilities and industrial zones is also encouraging partnerships between manufacturers and contract sterilisation providers, supporting long-term market growth while enhancing regional supply chain resilience and regulatory readiness. For instance, in May 2024, Becton, Dickinson and Company (BD) continued expanding manufacturing and healthcare support capabilities across emerging markets, reinforcing the need for validated sterilisation services to ensure product safety and regulatory compliance.

Middle East and Africa Offsite Sterilisation Service Market Scope

The Middle East and Africa offsite sterilisation service market is segmented on the basis of service technology, product type, application, and end user.

• By Service Technology

On the basis of service technology, the Middle East and Africa offsite sterilisation service market is segmented into Ethylene Oxide Sterilisation, Gamma Sterilisation, Electron Beam Sterilisation, Steam Sterilisation, NO2 Sterilisation, and Others. The Ethylene Oxide Sterilisation segment dominated the market with an estimated 44.82% share in 2025, owing to its extensive compatibility with heat- and moisture-sensitive medical devices and complex healthcare products. The technology is widely utilized by medical device manufacturers due to its ability to penetrate intricate packaging and sterilise large product volumes efficiently. It supports regulatory compliance requirements while maintaining product integrity and functionality. Growing demand for disposable medical devices and surgical products is further supporting adoption. Service providers continue to invest in advanced EtO process controls and emissions management systems. Its versatility and established validation standards continue to reinforce market leadership across the region.

The Gamma Sterilisation segment is projected to register the fastest growth at a CAGR of 7.2% from 2026 to 2033, driven by increasing demand for high-volume sterilisation of single-use medical products and pharmaceutical packaging. Gamma technology offers deep penetration capabilities and provides highly reliable sterility assurance for packaged products. The method is gaining popularity due to its efficiency, scalability, and ability to process products in their final packaging configuration. Expanding healthcare infrastructure and growing pharmaceutical manufacturing activities are contributing to rising demand. Increasing emphasis on infection prevention and product safety is accelerating adoption among healthcare suppliers. Continuous improvements in irradiation technologies and facility expansion initiatives are expected to further support segment growth.

• By Product Type

On the basis of product type, the Middle East and Africa offsite sterilisation service market is segmented into medical devices, surgical instruments, pharmaceutical products, biopharmaceutical products, laboratory equipment, healthcare consumables, and others. The Medical Devices segment led the market with an estimated 39.67% share in 2025, driven by rising production and consumption of sterile medical products across hospitals and healthcare facilities. Manufacturers increasingly rely on offsite sterilisation providers to ensure compliance with international quality standards and regulatory requirements. The growing adoption of single-use devices is creating substantial sterilisation demand. Outsourcing enables companies to reduce operational costs while accessing validated sterilisation technologies. Expanding healthcare investments and increasing surgical procedure volumes are further supporting growth. The segment continues to benefit from technological advancements in device design and healthcare delivery systems.

The Biopharmaceutical Products segment is expected to witness the fastest growth at a CAGR of 7.5% from 2026 to 2033, driven by expanding biotechnology research, biologics manufacturing, and advanced therapeutic development. These products require highly controlled sterilisation processes to maintain efficacy and product quality. Growing investments in pharmaceutical innovation and life sciences infrastructure are creating new opportunities for specialized sterilisation services. Regulatory agencies are increasingly emphasizing sterility assurance and contamination control throughout production processes. The rise of personalized medicine and biologic therapies is further increasing demand. Continuous expansion of regional pharmaceutical capabilities is expected to accelerate segment growth throughout the forecast period.

• By Application

On the basis of application, the Middle East and Africa offsite sterilisation service market is segmented into medical device sterilisation, pharmaceutical sterilisation, surgical equipment sterilisation, packaging sterilisation, laboratory material sterilisation, and others. The Medical Device Sterilisation segment dominated the market with an estimated 42.54% share in 2025, owing to increasing demand for sterile disposable products, diagnostic devices, and implantable medical equipment. Medical device manufacturers require validated sterilisation services to meet strict safety and regulatory requirements. Outsourcing sterilisation enables faster production cycles and improved operational efficiency. Growing healthcare expenditures and rising surgical intervention rates are supporting demand for sterile devices. Continuous innovation in medical technologies is generating additional sterilisation requirements. The segment remains the primary revenue contributor due to its broad product coverage and consistent demand.

The Pharmaceutical Sterilisation segment is anticipated to grow at the fastest CAGR of 7.3% from 2026 to 2033, driven by increasing pharmaceutical manufacturing activities and expanding demand for sterile drug products. Pharmaceutical companies are strengthening quality assurance programs to comply with international regulatory standards. Rising production of injectable drugs, vaccines, and specialty therapeutics is creating significant sterilisation requirements. Contract sterilisation providers offer scalable solutions that reduce operational complexity and capital investment needs. Growing healthcare access and pharmaceutical consumption across regional markets are supporting demand. Increasing focus on product safety and contamination prevention is expected to sustain long-term growth.

• By End User

On the basis of end user, the Middle East and Africa offsite sterilisation service market is segmented into hospitals, clinics, medical device companies, pharmaceutical companies, food & beverage companies, academic & research institutes, and others. The Medical Device Companies segment accounted for the largest market share of 37.91% in 2025, driven by growing production of disposable medical products and increasing regulatory requirements for sterility assurance. These companies extensively utilize contract sterilisation services to streamline operations and ensure compliance with international standards. Outsourcing eliminates the need for significant investments in in-house sterilisation infrastructure. Rising exports of medical devices and growing regional manufacturing capabilities are further supporting demand. The segment also benefits from increasing adoption of advanced sterilisation technologies. Strong focus on product quality and patient safety continues to strengthen its market position.

The Pharmaceutical Companies segment is projected to register the fastest growth at a CAGR of 7.4% from 2026 to 2033, supported by increasing investments in pharmaceutical manufacturing and healthcare modernization initiatives. Pharmaceutical producers require reliable sterilisation services for drug products, packaging materials, and production components. Growing demand for sterile injectable therapies and biologic medicines is accelerating outsourcing activities. Service providers offer validated processes that help manufacturers meet stringent regulatory expectations. Expansion of local pharmaceutical production facilities is creating new growth opportunities across the region. Rising emphasis on supply chain quality, product integrity, and regulatory compliance is expected to drive sustained segment expansion.

Middle East and Africa Offsite Sterilisation Service Market Regional Analysis

Saudi Arabia dominated the Middle East and Africa offsite sterilisation service market with the largest revenue share of 34.28% in 2025, supported by expanding healthcare infrastructure, increasing medical device consumption, and strong government healthcare investments. The country also benefits from a growing pharmaceutical sector, rising demand for sterile medical products, and the presence of advanced healthcare facilities requiring compliant sterilisation services. Increasing adoption of outsourced sterilisation solutions among hospitals, medical device manufacturers, and pharmaceutical companies is further supporting market growth. Strong focus on infection prevention, regulatory compliance, and healthcare quality standards continues to strengthen Saudi Arabia’s leadership position in the Middle East and Africa offsite sterilisation service market.

The Saudi Arabia Offsite Sterilisation Service Market Insight

The Saudi Arabia offsite sterilisation service market is witnessing strong growth due to rising investments in healthcare infrastructure, increasing medical device consumption, and growing demand for infection prevention solutions. The country’s expanding pharmaceutical and healthcare sectors, along with increasing adoption of outsourced sterilisation services, are driving demand across hospitals, medical device manufacturers, and pharmaceutical companies. In addition, growing emphasis on regulatory compliance, patient safety standards, and healthcare modernization initiatives is accelerating the utilization of advanced sterilisation technologies throughout the country.

United Arab Emirates Offsite Sterilisation Service Market Insight

The United Arab Emirates offsite sterilisation service market is experiencing steady growth, supported by increasing adoption of advanced healthcare technologies, expanding pharmaceutical activities, and rising demand for sterile medical products. Growing investments in healthcare infrastructure and increasing preference for outsourced sterilisation solutions are contributing to market expansion. Furthermore, the implementation of stringent healthcare quality standards and the development of specialized medical and industrial zones are improving service accessibility and operational efficiency, positioning the UAE as a key growth market within the region.

South Africa Offsite Sterilisation Service Market Insight

The South Africa offsite sterilisation service market is expanding steadily due to the country’s established healthcare sector, growing medical device usage, and increasing focus on infection prevention. Hospitals, pharmaceutical manufacturers, and healthcare suppliers are increasingly utilizing contract sterilisation services to ensure product safety and regulatory compliance. Continuous improvements in healthcare infrastructure, rising awareness regarding sterile healthcare practices, and increasing demand for cost-effective sterilisation solutions are further supporting market growth in South Africa.

Qatar Offsite Sterilisation Service Market Insight

The Qatar offsite sterilisation service market is witnessing consistent growth due to rising investments in healthcare infrastructure, increasing healthcare expenditure, and growing focus on patient safety initiatives. Healthcare providers, pharmaceutical companies, and medical suppliers are increasingly utilizing specialised sterilisation services to ensure compliance with international quality standards. Moreover, expanding healthcare facilities and the country’s commitment to advanced healthcare delivery systems are further contributing to market growth.

Middle East and Africa Offsite Sterilisation Service Market Share

The Middle East and Africa offsite sterilisation service industry is primarily led by well-established companies, including:

• Sterigenics International LLC (U.S.)
• Nelson Laboratories, LLC (U.S.)
• Sotera Health LLC (U.S.)
• IONISOS (France)
• BGS Beta-Gamma-Service GmbH & Co. KG (Germany)
• BBF Sterilisationsservice GmbH (Germany)
• Medistri SA (Switzerland)
• STERIS plc (Ireland)
• SteriPack Group (Ireland)
• Synergy Health Holdings Limited (U.K.)
• STERIXENE LIMITED (U.K.)
• Isotron Nederland B.V. (Netherlands)
• Isotron Deutschland GmbH (Germany)
• Beta-Gamma-Service Nederland B.V. (Netherlands)
• TEC Eurolab Srl (Italy)
• Bio-Steril NV (Belgium)
• Steripure SAS (France)
• LEONI Elocab GmbH (Germany)
• Steri-Tek SAS (France)
• Microtrol Sterilisation Services Pvt. Ltd. (India)

Latest Developments in Middle East and Africa Offsite Sterilisation Service Market

• In June 2025, Solventum, a leading healthcare technology company, announced the launch of its Attest™ Super Rapid Vaporized Hydrogen Peroxide (VH₂O₂) Clear Challenge Pack, designed to simplify sterilization monitoring and validation processes for healthcare facilities. The solution combines biological and chemical indicators in a single package, helping improve workflow efficiency and sterility assurance for low-temperature sterilization applications. This development supports the growing demand for advanced sterilization technologies used by hospitals and contract sterilization service providers globally
• In November 2024, Advanced Sterilization Products (ASP), a leading provider of infection prevention and sterilization solutions, received four Medical Device Network Excellence Awards for innovation, safety, environmental performance, and product development. The recognition was driven by the company’s ULTRA GI™ Cycle for the STERRAD™ 100NX Sterilizer, which enhances sterilization capabilities for complex medical devices. The achievement highlights ongoing technological advancements supporting the offsite sterilization services industry
• In July 2024, Getinge, a global healthcare technology company, expanded the commercialization of its Poladus 150 sterilization platform as part of its broader infection control portfolio strategy. The solution was introduced to address growing demand for safe and efficient reprocessing of advanced surgical and endoscopic instruments while supporting healthcare providers with enhanced sterilization capacity. This development demonstrates the industry's continued focus on improving sterilization performance and operational efficiency
• In June 2024, Getinge, a leading provider of infection control and healthcare equipment, announced the launch of the Poladus 150 low-temperature sterilizer, developed to sterilize heat-sensitive surgical instruments and medical devices. The system incorporates advanced vaporized hydrogen peroxide technology and enhanced contamination-control features, enabling healthcare facilities to improve sterilization efficiency and compliance. The launch reflects increasing industry investment in modern sterilization infrastructure and infection prevention solutions
• In March 2024, the U.S. Environmental Protection Agency (EPA) finalized new ethylene oxide emission standards for commercial sterilization facilities, establishing stricter environmental requirements while maintaining sterilization capacity for critical medical devices. The updated regulations are expected to encourage investment in cleaner and more advanced sterilization technologies across the industry. This development is influencing sterilization service providers worldwide as they adapt operations to meet evolving regulatory and sustainability requirements

SKU-68915